O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+55.65%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.98B
AUM Growth
+$6.98B
(+34%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
37.73%
Holding
152
New
37
Increased
17
Reduced
34
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$109M |
| 2 |
89bio
ETNB
|
$105M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$104M |
| 4 |
Danaher
DHR
|
$98.1M |
| 5 |
Glaukos
GKOS
|
$84.3M |
Top Sells
| 1 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$96.3M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
$79.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$68.7M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$58.9M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$56.6M |
Sector Composition
| 1 | Healthcare | 98.02% |
| 2 | Financials | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $465M | 6.64% | 3,343,100 -376,073 | -10% | -$52.3M |
|
|
THOR
2
DELISTED
Synthorx, Inc. Common Stock
THOR
| $372M | 5.3% | 5,316,355 | – | – |
|
|
TCDA
3
DELISTED
Tricida, Inc. Common Stock
TCDA
| $363M | 5.18% | 9,614,280 -1,500,000 | -13% | -$56.6M |
|
|
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
| $285M | 4.07% | 7,406,307 | – | – |
|
|
PRVL
5
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $219M | 3.12% | 13,822,463 | – | – |
|
6
Boston Scientific
BSX
$156B
| $211M | 3.02% | 4,674,800 -593,900 | -11% | -$26.9M |
|
7
Alector
ALEC
$238M
| $189M | 2.7% | 10,987,944 -1,544,385 | -12% | -$26.6M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $180M | 2.57% | 1,662,585 -700 | -0% | -$75.7K |
|
9
Merck
MRK
$210B
| $178M | 2.54% | 1,954,100 | – | – |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $173M | 2.47% | 1,340,600 +805,457 | +151% | +$104M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $171M | 2.45% | 783,100 -63,300 | -7% | -$13.9M |
|
|
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $171M | 2.44% | 2,745,327 | – | – |
|
13
Iovance Biotherapeutics
IOVA
$807M
| $154M | 2.19% | 5,548,326 | – | – |
|
14
NextCure
NXTC
$13.5M
| $153M | 2.18% | 2,711,013 | – | – |
|
15
Humana
HUM
$36.5B
| $144M | 2.05% | 391,900 +210,100 | +116% | +$77M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $109M | 1.56% | +1,700,000 | New | +$109M |
|
17
eHealth
EHTH
$118M
| $107M | 1.53% | 1,111,914 -5,500 | -0.5% | -$528K |
|
|
18
89bio
ETNB
$1.34B
| $105M | 1.5% | +4,004,442 | New | +$105M |
|
19
Edwards Lifesciences
EW
$47.8B
| $101M | 1.45% | 434,900 -72,900 | -14% | -$17M |
|
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $101M | 1.44% | 935,970 -639,200 | -41% | -$68.7M |
|
21
Cigna
CI
$80.3B
| $100M | 1.43% | 489,700 +198,100 | +68% | +$40.5M |
|
22
Inspire Medical Systems
INSP
$2.77B
| $100M | 1.43% | 1,347,000 -124,000 | -8% | -$9.2M |
|
|
ARQL
23
DELISTED
Arqule Inc
ARQL
| $99.8M | 1.42% | 5,000,000 +1,298,727 | +35% | +$25.9M |
|
24
Intuitive Surgical
ISRG
$170B
| $99.2M | 1.42% | 167,800 -37,800 | -18% | -$22.3M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $98.9M | 1.41% | 766,049 -71,300 | -9% | -$9.2M |
|